Pragmatic McDa Combined With Advanced Pharmacoepidemiology for Quantitative Benefit/Risk Assessments of Medicines

Value in Health - United Kingdom
doi 10.1016/j.jval.2014.03.191
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Procedures and Methods of Benefit Assessments for Medicines in Germany

European Journal of Health Economics
Health PolicyEconomicsEconometricsFinance
2008English

Patient Preferences in Regulatory Benefit-Risk Assessments: A US Perspective

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2016English

Benefit of Whole Pelvic Radiotherapy Combined With Neoadjuvant Androgen Deprivation for the High-Risk Prostate Cancer

Journal of Biomedicine and Biotechnology
2009English

Incremental Predictive Value of Vascular Assessments Combined With the Framingham Risk Score for Prediction of Coronary Events in Subjects of Low-Intermediate Risk

Postgraduate Medical Journal
Medicine
2008English

Explosion Risk Assessments for Facilities With Compressed Flammable Gases

TRANSACTIONS of the VŠB – Technical University of Ostrava, Safety Engineering Series
2015English

Patient-Focused Drug Development Methods for Benefit-Risk Assessments: A Case Study Using Discrete Choice Experiment for Antiepileptic Drugs

Clinical Pharmacology and Therapeutics
Pharmacology
2018English

Herbal Medicines and Epilepsy: The Potential for Benefit and Adverse Effects

Epilepsy and Behavior
NeurologyBehavioral Neuroscience
2001English

Iqwig Early Benefit Assessments of Type 2 Diabetes Therapies

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

Assessing a Structured, Quantitative Health Outcomes Approach to Drug Risk-Benefit Analysis

Health Affairs
MedicineHealth Policy
2007English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy